Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.72 USD | -0.91% | +0.21% | +96.50% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+96.50% | 2.27B | |
+20.95% | 47.02B | |
+49.45% | 41.86B | |
-0.20% | 41.76B | |
-4.27% | 28.8B | |
+11.49% | 26.05B | |
-21.11% | 19.15B | |
+2.99% | 12.55B | |
+31.50% | 12.34B | |
-3.00% | 11.82B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating